FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3119953938> ?p ?o ?g. }

• W3119953938 endingPage "50" @default.
• W3119953938 startingPage "37" @default.
• W3119953938 abstract "AbstractThe severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that causes the coronavirus disease 2019 (COVID-19) has infected millions of individuals and has claimed hundreds of thousands of human lives worldwide. Patients with underlying cardiovascular conditions are at high risk for SARS-CoV-2 infection, and COVID-19 patients have high incidence of cardiovascular complications such as acute cardiac injury, arrhythmias, heart failure, and thromboembolism. The disease has no approved proven effective therapy and hence repurposing of existing approved drugs has been considered as the fastest treatment approach. Statins have been shown to exhibit lipid lowering dependent and independent cardiovascular protective effects as well as favorable effects in various other pathophysiological states. These beneficial properties of statins are a result of their multiple pleotropic effects that include, anti-inflammatory, immunomodulatory, antithrombotic and antimicrobial properties. In this review, we provide a comprehensive description of the mechanisms of the pleotropic effects of statins, the relevant pre-clinical and clinical data pertinent to their role in infections and acute lung injury, the possible cardiovascular benefits of statins in COVID-19, and the implications of the therapeutic potential of statins in COVID-19 disease. We conclude with the rationale for conducting randomized controlled trials of statins in COVID-19 disease.Keywords: StatinsCOVID-19antiviralanti-inflammatoryacute lung injurySARS-CoV-2ARDSimmunomodulatory Disclosure statementDr. O'Horo reports personal fees from Elsevier, Inc, outside the submitted work. Dr. Tleyjeh reports other from pToDate, outside the submitted work. Dr. Badely: Consultant: Abbvie, Nference, Qrativ, Zeno Pharmaceuticals. Other: SAB: Nference, Zentalis. Founder and President, Splissen Therapeutics. Program Director/Principal Investigator Grants. Evaluating the role of the novel apoptosis inhibitor TRAILshort, in maintaining HIV persistence. Funded by National Institute of Allergy and Infectious Diseases. (R01 AI 120698). Prime shock and kill for HIV eradication. Funded by National Institute of Allergy and Infectious Diseases (R01 AI 110173). Ixazomib to reduce HIV reservoir size. Funded by AmFar (109593-62-RGRL). Dr Arabi reports that he is principal investigator on a clinical trial of lopinavir–ritonavir and interferon for Middle East respiratory syndrome (MERS) and that he was a non-paid consultant on therapeutics for MERS-coronavirus (CoV) for Gilead Sciences and SAB Biotherapeutics. He is a co-investigator on the Randomized, Embedded, Multi-factorial Adaptive Platform Trial for Community-Acquired Pneumonia (REMAP-CAP) and a board member of the International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC). Other authors: nothing to disclose." @default.
• W3119953938 created "2021-01-18" @default.
• W3119953938 creator A5005832956 @default.
• W3119953938 creator A5021200051 @default.
• W3119953938 creator A5022761201 @default.
• W3119953938 creator A5041180761 @default.
• W3119953938 creator A5041348140 @default.
• W3119953938 creator A5077252735 @default.
• W3119953938 creator A5083611413 @default.
• W3119953938 date "2021-01-02" @default.
• W3119953938 modified "2023-10-08" @default.
• W3119953938 title "Statins as an adjunctive therapy for COVID-19: the biological and clinical plausibility" @default.
• W3119953938 cites W1480408416 @default.
• W3119953938 cites W1525331105 @default.
• W3119953938 cites W1545863889 @default.
• W3119953938 cites W179406719 @default.
• W3119953938 cites W1904552307 @default.
• W3119953938 cites W1968955127 @default.
• W3119953938 cites W1970106273 @default.
• W3119953938 cites W1976350013 @default.
• W3119953938 cites W1980857453 @default.
• W3119953938 cites W1982466829 @default.
• W3119953938 cites W1986949841 @default.
• W3119953938 cites W1998744919 @default.
• W3119953938 cites W2000915997 @default.
• W3119953938 cites W2006572302 @default.
• W3119953938 cites W2006623674 @default.
• W3119953938 cites W2009470002 @default.
• W3119953938 cites W2010733432 @default.
• W3119953938 cites W2012582908 @default.
• W3119953938 cites W2024815256 @default.
• W3119953938 cites W2029473819 @default.
• W3119953938 cites W2029491963 @default.
• W3119953938 cites W2030918082 @default.
• W3119953938 cites W2033023829 @default.
• W3119953938 cites W2035933971 @default.
• W3119953938 cites W2036295658 @default.
• W3119953938 cites W2040785340 @default.
• W3119953938 cites W2046738822 @default.
• W3119953938 cites W2051062943 @default.
• W3119953938 cites W2067590199 @default.
• W3119953938 cites W2070307339 @default.
• W3119953938 cites W2072318687 @default.
• W3119953938 cites W2073861766 @default.
• W3119953938 cites W2076834039 @default.
• W3119953938 cites W2077412704 @default.
• W3119953938 cites W2079860336 @default.
• W3119953938 cites W2087917437 @default.
• W3119953938 cites W2095956260 @default.
• W3119953938 cites W2096079570 @default.
• W3119953938 cites W2097224246 @default.
• W3119953938 cites W2106410542 @default.
• W3119953938 cites W2110951885 @default.
• W3119953938 cites W2112261869 @default.
• W3119953938 cites W2112659240 @default.
• W3119953938 cites W2124720109 @default.
• W3119953938 cites W2124826485 @default.
• W3119953938 cites W2125870353 @default.
• W3119953938 cites W2144896295 @default.
• W3119953938 cites W2145736817 @default.
• W3119953938 cites W2149980324 @default.
• W3119953938 cites W2161834691 @default.
• W3119953938 cites W2164013535 @default.
• W3119953938 cites W2169503288 @default.
• W3119953938 cites W2170236185 @default.
• W3119953938 cites W2271936122 @default.
• W3119953938 cites W2314796968 @default.
• W3119953938 cites W2466525039 @default.
• W3119953938 cites W2492632601 @default.
• W3119953938 cites W2551841976 @default.
• W3119953938 cites W2564354343 @default.
• W3119953938 cites W2570787279 @default.
• W3119953938 cites W2574620017 @default.
• W3119953938 cites W2737347025 @default.
• W3119953938 cites W2760448018 @default.
• W3119953938 cites W2767859172 @default.
• W3119953938 cites W2770333021 @default.
• W3119953938 cites W2777724025 @default.
• W3119953938 cites W2801251501 @default.
• W3119953938 cites W2885500852 @default.
• W3119953938 cites W2894810674 @default.
• W3119953938 cites W2897035420 @default.
• W3119953938 cites W2899027857 @default.
• W3119953938 cites W2900829362 @default.
• W3119953938 cites W2914546434 @default.
• W3119953938 cites W2945248317 @default.
• W3119953938 cites W2949816423 @default.
• W3119953938 cites W2952565102 @default.
• W3119953938 cites W3002108456 @default.
• W3119953938 cites W3009828712 @default.
• W3119953938 cites W3009885589 @default.
• W3119953938 cites W3011792889 @default.
• W3119953938 cites W3012655019 @default.
• W3119953938 cites W3012747666 @default.
• W3119953938 cites W3013231340 @default.
• W3119953938 cites W3013648910 @default.
• W3119953938 cites W3014003872 @default.
• W3119953938 cites W3015841799 @default.

• next